论文部分内容阅读
目的:调查乙肝相关性肝癌患者CMV-pp65抗原血症情况,探讨CMV-pp65抗原检测的临床意义。方法:采用免疫组化二步法和酶联免疫吸附反应法(ELISA)检测30例乙肝相关性肝癌患者CMV-pp65抗原和CMV特异性IgM抗体;同时检测18例健康体检者的CMV-pp65抗原设为对照组,采用卡方检验进行统计分析。结果:30例乙肝相关性肝癌患者中CMV-pp65抗原血症阳性13例,阳性率43.3%(13/30);CMV特异性IgM抗体阳性2例,阳性率6.7%(2/30),经卡方检验,χ2=10.756,P<0.01,对比组之间的差异具有统计学意义。对照组18例健康体检者CMV-pp65抗原血症阳性0例,经卡方检验,χ2=10.697,P<0.01,对比组之间的差异具有统计学意义。结论:乙肝相关性肝癌患者CMV-pp65抗原血症阳性率高,提示活动性CMV感染;CMV-IgM抗体检测不适合肝癌患者活动性CMV感染的早期诊断。
Objective: To investigate the CMV-pp65 antigenemia in patients with hepatitis B-related liver cancer and to explore the clinical significance of detection of CMV-pp65 antigen. Methods: CMV-pp65 antigen and CMV-specific IgM antibody were detected in 30 patients with HBV-related hepatocellular carcinoma by immunohistochemical two-step method and enzyme linked immunosorbent assay (ELISA); CMV-pp65 antigen Set as a control group, using chi-square test for statistical analysis. Results: The positive rate of CMV-pp65 antigen was 13.3% (13/30) in 30 cases of hepatitis B-related liver cancer. The positive rate of CMV-specific IgM was 6.7% (2/30) Chi-square test, χ2 = 10.756, P <0.01, the difference between the control group was statistically significant. The control group of 18 cases of healthy subjects CMV-pp65 antigen-positive 0 cases, the chi-square test, χ2 = 10.697, P <0.01, the difference between the control group was statistically significant. Conclusion: The positive rate of CMV-pp65 antigen in patients with HBV-related liver cancer is high, suggesting active CMV infection. The detection of CMV-IgM antibody is not suitable for the early diagnosis of active CMV infection in patients with liver cancer.